U.S. market Closed. Opens in 17 hours 11 minutes

BPTH | Bio-Path Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.9664 - 1.0599
52 Week Range 0.9100 - 21.60
Beta -0.37
Implied Volatility 776.41%
IV Rank 9.31%
Day's Volume 105,681
Average Volume 359,843
Shares Outstanding 2,552,190
Market Cap 2,551,680
Sector Healthcare
Industry Biotechnology
IPO Date 2008-03-04
Valuation
Profitability
Growth
Health
P/E Ratio -0.07
Forward P/E Ratio N/A
EPS -14.19
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 10
Country USA
Website BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
*Chart delayed
Analyzing fundamentals for BPTH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see BPTH Fundamentals page.

Watching at BPTH technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on BPTH Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙